



Novelx Pharmaceuticals limited
(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(TRIMURTHI | 536565 | INE314I01036)

Date: 12.02.2025

To
The General Manager - Operations,
BSE Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

Dear Sir/Ma'am,

Sub: Integrated Filing (Financial) - Financial Results for the Quarter ended 31st December, 2024

Ref: Scrip Code: 536565 - Trimurthi Limited (ISIN: INE314I01036)

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, please find enclosed herewith the Integrated Filing (Financial) for the quarter and nine months ended 31st December, 2024.

The Board of Directors of the Company at their meeting held on Wednesday, 12th February, 2025 at 5 P.M. and concluded at 5:30 P.M. Inter alia, considered and approved the unaudited Financial Results for the Quarter ended 31st December, 2024.

Copy of unaudited Financial Results for the Quarter ended 31st December, 2024, along with copy of Limited Review Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,
Yours faithfully,
For NOVELIX PHARMACEUTICALS LIMITED
(formerly known as Trimurthi Limited)

Venkat



Venkateshwarlu Pulluru
Whole Time Director
DIN: 02076871
Address: D. No :1-7-878/3, Jayasree Enclave, Hunter Road,
Hanamkoda, Warangal – 506001, Telangana

Encl: As above

Novelx Pharmaceuticals limited
(Formerly TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar,
Hyderabad, Telangana - 500028 Email: novelxpharmaceuticals@gmail.com

NOVELIX PHARMACEUTICALS LIMITED
 Regd Off: 6th Floor,3-6-237/610,Lingapur LA Build Complex, Himayathnagar, Hyderabad, Telangana – 500029
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER III AND NINE MONTHS ENDED 31st DECEMBER 2024

Amount(Rs in lakhs except EPS)

PARTICULARS	Quarter Ended	Preceding Quarter Ended	Corresponding Quarter Ended in Previous Year	9 Months Ended	Corresponding 9 Months Ended in Previous Year	YEAR ENDED
	31.12.2024 (UNAUDITED)	30.09.2024 (UNAUDITED)	31.12.2023 (UNAUDITED)	31.12.2024 (UNAUDITED)	31.12.2023 (UNAUDITED)	31.03.2024 (AUDITED)
1. INCOME						
INCOME FROM OPERATIONS	529.98	383.95	49.88	985.75	338.09	422.38
OTHER INCOME	0.11	3.43	8.50	1.60	17.82	30.74
TOTAL INCOME	530.09	387.37	58.38	987.35	355.91	453.12
2. EXPENSES						
PURCHASES	561.14	302.93	53.27	900.64	346.17	421.02
COST OF MATERIALS CONSUMED	0.00	0.00	0.00	0.00	0.00	0.00
MANUFACTURING EXPENSES	0.00	0.00	0.00	0.00	0.00	0.00
INCREASE/(DECREASE) IN STOCK IN TRADE	-58.95	45.33	-7.14	28.35	-19.06	-37.39
RENT	0.00	0.00	0.30	0.00	0.90	1.20
EMPLOYEE BENEFITS EXPENSE	0.78	1.71	0.00	6.13	12.26	15.43
FINANCE COSTS	0.00	0.00	3.98	0.00	0.00	0.00
DEPRECIATION AND AMORTISATION EXPENSES	0.49	0.48	1.06	1.46	3.20	3.81
OTHER EXPENSES	13.84	23.84	10.28	59.49	38.10	46.91
TOTAL EXPENSES	517.29	374.30	61.75	996.07	381.57	450.99
3. PROFIT/(LOSS) FROM BEFORE EXCEPTIONAL ITEMS AND TAX (1-2)	12.80	13.07	-3.37	-8.72	-25.66	2.13
4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS	0.00	0.00	0.00	0.00	0.00	0.00
5. PROFIT/(LOSS) FROM CONTINUING OPERATIONS BEFORE TAX (3-4)	12.80	13.07	-3.37	-8.72	-25.66	2.13
6. TAX EXPENSES	-1.99	0.12	0.00	1.07	0.96	1.08
-CURRENT TAX	0.00	0.00	-1.08	0.00	0.00	1.08
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS	0.00	0.00	0.00	0.00	0.00	0.00
-DEFERRED TAX (NET)	-1.99	0.12	0.40	1.07	0.96	1.08
7. NET PROFIT/(LOSS) FROM CONTINUING OPERATIONS AFTER TAX (5-6)	14.79	12.95	-2.97	-7.65	-26.62	1.04
8. PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS	0.00	0.00	0.00	0.00	0.00	0.00
9. TAX EXPENSES FOR DISCONTINUED OPERATIONS	0.00	0.00	0.00	0.00	0.00	0.00
10. PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)	0.00	0.00	0.00	0.00	0.00	0.00
11. PROFIT/(LOSS) FOR THE PERIOD (7+10)	14.79	12.95	-2.97	-7.65	-26.62	1.04
12. OTHER COMPREHENSIVE INCOME						
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	0.00	0.00	4.83	0.00	15.23	14.92
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	0.00	0.00	0.00	0.00	0.00	0.00
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	0.00	0.00	0.00	0.00	0.00	0.00
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	0.00	0.00	0.00	0.00	0.00	0.00
13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)	14.79	12.95	1.86	-7.65	-11.39	15.97
14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION) :						
(i) BASIC	0.15	0.16	0.04	-0.08	-0.33	0.01
(ii) DILUTED	0.16	0.16	0.04	-0.08	-0.33	0.01
15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION) :						
(i) BASIC						
(ii) DILUTED						
16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION) :						
(i) BASIC	0.15	0.16	0.04	-0.08	-0.33	0.01
(ii) DILUTED	0.16	0.16	0.04	-0.08	-0.33	0.01

Note: Q2 revenue made classification change, no change in overall revenue and expenses numbers as well EPS

Venkiel



Working for Segment Revenue & Segment Profit:

	Pharma Business	Investment in Shares	Trading in shares	Foods	Finance	Total
I. Revenue						
-Sales	97,403.55					97,403.55
-Other Income		1,171.17			159.58	1,330.75
	97,403.55	1,171.17	-	-	159.58	98,734.30
	974.04	11.71	-	-	1.60	987.34
II. Expenditure						
-Purchase	-					-
-Cost of Material consumed	90,064.25	-				90,064.25
-Manufacturing Exp	-	-				-
-Changes in Inventory	2,835.23					2,835.23
-Employee Benefits Expenses	613.00					613.00
-Finance Cost						-
-Depreciation & Amortization Expense	145.50					145.50
-Other Expenses	5,948.62					5,948.62
						-
						-
						-
	99,606.60	-	-	-	-	99,606.60
Profit/ (Loss)	(2,203.05)	1,171.17	-	-	159.58	(872.29)
Less: Income Tax Paid for Earlier Years						-
	(2,203.05)	1,171.17	-	-	159.58	(872.29)
	(22.030)	11.712	-	-	1.596	(8.723)

Venkata





CVS. Balachandra Rao & Co.,
Chartered Accountants

Limited Review Report on Standalone Unaudited Quarterly Financial Results of Novelix Pharmaceuticals Limited (Formerly Trimurthi Limited) pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
Board of Directors
Novelix Pharmaceuticals Limited
(Formerly known as Trimurthi Limited)


We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **Novelix Pharmaceuticals Limited (Formerly known as Trimurthi Limited)** for the quarter ended on 31st December, 2024, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CVS Balachandra Rao & Co.,
Chartered Accountants
ICAI Firm Registration Number: 007507S


CVS Balachandra Rao
Partner
Membership Number: 204580
UDIN: 25204580BMHYVY2279
Date: 12/02/2025
Place: Hyderabad





Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(TRIMURTHI | 536565 | INE314101036)

QUARTERLY INTEGRATED FILING (FINANCIAL)

- A. FINANCIAL RESULTS: Attached.
- B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.: Not Applicable.
- C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES: Not applicable.
- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS: Not Applicable for the quarter ended 31st December, 2024.
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS: Not Applicable for the quarter ended 31st December, 2024.

Venkat



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad. Telangana- 500029 Email: novelixpharmaceuticals@gmail.com